(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination - 2Eurasian cargo hub expands to capture Europe-Asia freight flows
- 3Journalists killed by Israeli strike in southern Lebanon
- 4Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- 5Israeli strike on Gaza City vehicle kills at least four, report says
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Dozens killed as Angola flood death toll rises
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Brazil expands pesticide packaging reverse logistics
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- Farmers call for French blockades over cow disease cull
